# Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas

> **NCT02076451** · PHASE1 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 32 (actual)

## Conditions studied

- Advanced Solid Tumor
- Lymphoma

## Interventions

- **DRUG:** DS-8273a

## Key facts

- **NCT ID:** NCT02076451
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2019-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02076451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02076451, "Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02076451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*